Scripps HIV Protection Grant: NIH Funds Long-Term Research
- Nearly 40 years after human Immunodeficiency Virus (HIV) was first identified, the virus continues to pose a significant global health threat.
- Scripps Research has been awarded a five-year, $6.9 million grant from the National Institutes of Health (NIH) to address the critical challenge of creating a lasting HIV...
- "We've learned how to generate strong initial immune responses in patients, but we haven't cracked the code for making them durable enough to treat HIV.
“`html
Scripps Research Receives $6.9 Million NIH Grant to Advance HIV Vaccine Progress
Table of Contents
The Ongoing Challenge of an HIV Vaccine
Nearly 40 years after human Immunodeficiency Virus (HIV) was first identified, the virus continues to pose a significant global health threat. As of today, approximately 38 million people are living with HIV. Each year, around 1.5 million new infections occur, resulting in approximately 650,000 deaths. Alarmingly, nearly 10 million people still lack access to life-saving antiretroviral therapies. Despite decades of intensive research and considerable progress in treatment, a durable and effective HIV vaccine remains elusive.
Scripps research project Details
Scripps Research has been awarded a five-year, $6.9 million grant from the National Institutes of Health (NIH) to address the critical challenge of creating a lasting HIV vaccine. The project, led by Bryan Briney, Associate Professor of the department of Immunology and Microbiology, is a collaborative effort bringing together expertise from multiple disciplines. Key collaborators include Renan de Carvalho, Assistant Professor in the Department of Immunology and Microbiology; Andrew Ward, professor in the Department of Integrative Structural and Computational Biology; and Darrell Irvine, Professor and Vice Chair of the Department of Immunology and Microbiology.
“We’ve learned how to generate strong initial immune responses in patients, but we haven’t cracked the code for making them durable enough to treat HIV. This project is about identifying the specific recipe-the right ingredients, the right amounts, the right timing-that creates protection lasting years or decades rather than months.”
– Bryan Briney, Associate Professor, Department of Immunology and microbiology, Scripps Research Institute
Following the Immune Response: A Novel Approach
A central component of this research involves utilizing a novel mouse model developed in Renan de carvalho’s lab. This model allows scientists to “tag” immune cells as they respond to a vaccine, enabling them to track the cells’ behaviour and lifespan over extended periods. the research focuses on understanding why some vaccine-activated cells quickly diminish, while others differentiate into long-lived plasma cells (LLPCs). LLPCs are essential for sustained antibody production and long-term protection against viruses.
“We can now timestamp these cells with unbelievable precision, knowing…
Understanding Long-Lived plasma Cells (LLPCs)
Long-lived plasma cells (LLPCs) are a critical component of durable immunity. These specialized cells reside in bone marrow and continuously produce antibodies, providing long-term protection against pathogens. The Scripps research team aims to identify the factors that promote the development and maintainance of LLPCs in response to an HIV vaccine.This includes investigating the specific signals and interactions that drive the differentiation of short-lived plasma cells into llpcs.
key Factors Influencing LLPC Development
- Antigen Presentation: How the vaccine antigen is presented to the immune system influences the type of immune response generated.
- T Cell Help: LLPC development requires assistance from T follicular helper cells.
- Cytokine Signals: Specific cytokines (signaling molecules) play a crucial role in promoting LLPC survival and